Cornovus Pharmaceuticals Inc.

Cornovus Pharmaceuticals Inc. is a for-profit corporate entity registered in SAM.gov since August 5, 2015, with an active registration through January 15, 2025. The company appears to be a pharmaceutical research organization focused on developing innovative drug therapies targeting specific medical conditions, particularly in the cardiovascular and neurological domains. As a research-oriented pharmaceutical company, Cornovus specializes in developing novel therapeutic approaches, with a particular emphasis on creating targeted drug candidates that address complex medical challenges such as stroke and heart failure.

The company has secured multiple federal grant awards from the National Heart, Lung, and Blood Institute (NHLBI), primarily focused on developing advanced therapeutic interventions. Specifically, Cornovus has been awarded grants for groundbreaking research in anti-inflammatory therapies for ischemic stroke, including a significant project (R41HL156322 and R42HL156322) developing small molecule antagonists targeting the P2X4 receptor to mitigate stroke-related inflammation. These grants demonstrate a collaborative approach, with Cornovus partnering with academic institutions like the University of Connecticut School of Medicine and leveraging expertise from NIH laboratories. Another grant (R44HL152710) focuses on developing a new drug therapy for advanced heart failure, further highlighting the company's commitment to cardiovascular medical research. The grants are structured as Project Grants, indicating a systematic approach to translational research with clear objectives of identifying lead compounds, conducting preclinical studies, and potentially preparing for FDA investigational new drug (IND) applications.